EXCLUSIVE: Kevin Harrington Becomes The Latest 'Shark Tank' Judge To Enter The Psychedelics Space

The psychedelics industry is quickly becoming the latest playground for celebrity investors and influencers in the financial sphere.

Kevin Harrington, one of the original “sharks” in ABC's “Shark Tank” is joining a psychedelics company as an investor and strategic advisor.

The company, Psycheceutical, Inc., is a wholly-owned subsidiary of Psycheceutical Bioscience, Inc. BWVI - a biotech currently developing patented delivery technologies designed to increase the safety and efficacy of psychedelic compounds.

“We need a different approach to treatment, and psychedelic medicines have shown incredible promise where conventional medicines have failed. It seems clear to me that psychedelics are the future of mental health treatment, but they need to be delivered safely like pharmaceutical medicines, which is why I’m so excited about Psycheceutical,” Harrington said.

Another Shark Dives Into The Psychedelics Tank

Harrington’s announcement adds weight to the growing presence of Shark Tank judges in the psychedelics space. In 2020 Kevin O’Leary, who shared two seasons of the show with Harrington, entered the space with an initial investment in MindMed MNMD, taking further positions in Compass Pathways CMPS.

 

 

O’Leary shared his vision for investing in the psychedelics space during a live keynote last month at Benzinga’s Psychedelics Capital Conference.

Other famed investors involved in psychedelics-related investing include Peter Thiel and Cathie Wood.

Related: Cathie Wood Finds Elon Musk's Comment On Psychedelics, Ketamine An 'Interesting Thesis' For This Stock

“The world is undergoing an unprecedented mental health crisis – we all know someone who is suffering from depression, anxiety, or addiction. What we’ve been doing isn’t working,” Harrington said. 

He said he’s been watching the emerging psychedelic medicine industry and that he chose to invest in and join Psycheceutical “because of their patented next-gen delivery technologies, designed to increase the safety and efficacy of psychedelic compounds without the hallucinogenic side effects.

“As an entrepreneur who is trying to help people and make a positive impact with my investments, these kinds of opportunities don’t come up that often: real solutions to help alleviate real suffering for millions of people,” Harrington concluded.

Photo by Milad Fakurian on Unsplash

Market News and Data brought to you by Benzinga APIs
Posted In: CannabisNewsPenny StocksPsychedelicsSmall CapExclusivesMarketsKevin HarringtonPsycheceutical
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Benzinga Cannabis Capital Conference is coming to Florida

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

Get your tickets now on bzcannabis.com – Prices will increase very soon!


Loading...